<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322972</url>
  </required_header>
  <id_info>
    <org_study_id>10-02576</org_study_id>
    <nct_id>NCT00322972</nct_id>
  </id_info>
  <brief_title>Trachoma Amelioration in Northern Amhara (TANA)</brief_title>
  <acronym>TANA</acronym>
  <official_title>Eliminating Trachoma With Repeat Mass Drug Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The WHO has initiated a program to eliminate trachoma, blinding eye infection caused by
      Chlamydia trachomatis, in large part by mass distributions of oral azithromycin. The proposed
      study will determine the frequency and treatment target of community-wide mass antibiotic
      treatment. We will also study the impact of mass antibiotic distribution on
      antibiotic-resistance in pneumococcus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a group-randomized trial to determine the frequency and treatment
      target of community-wide mass antibiotic treatment to eliminate trachoma. We will also study
      the impact of community-wide antibiotic distribution on antibiotic-resistance in
      pneumococcus. Communities in Goncha Siso Enese district of East Gojam Zone, Ethiopia will be
      randomly assigned to different treatment schemes and monitored to study the following
      research questions:

      Specific Aim 1. To determine whether biannual mass treatments is more likely to eliminate
      ocular chlamydia from hyper-endemic communities than annual mass treatments.

      Specific Aim 2. To determine whether children form a core group for the transmission of
      trachoma.

      Specific Aim 3. To determine whether latrine construction prevents the return of infection
      into a community after mass treatment.

      Specific Aim 4. To determine the effect of mass azithromycin treatments on antibiotic
      resistance in pneumococcus and the reduction in mortality.

      Specific Aim 5. To determine whether annual mass treatments are more likely to eliminate
      ocular chlamydia from hyper-endemic communities than biennial mass treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The average prevalence of ocular chlamydia infection in communities in an arm as determined by pooled NAAT (Nucleic Acid Amplification Test)(at 42 months for Aim 1, at 12 months for Aim 2, post-treatment relative to pre-treatment for Aim 3)</measure>
    <time_frame>42 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical active trachoma in community, as determined by the WHO simplified grading system</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Childhood (&gt;= 1 year of age) mortality, analyzed as 1-5, 6-10 years of age, and total</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrolide resistance in pneumococcus (% resistance over time, clustered by randomization unit)</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average prevalence of ocular chlamydia infection in annually and biennially treated communities as determined by pooled NAAT (Nucleic Acid Amplification Test)</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diversity measure in the conjunctival and nasopharyngeal microbiomes of children (age 0-9)</measure>
    <time_frame>0, 6, 12, 18, 24, 30, 36, 42, and 48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">33000</enrollment>
  <condition>Trachoma</condition>
  <condition>Chlamydia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Annual mass treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Biannual mass treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mass administration of antibiotic; treatment of children (1-10 years of age) only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Delayed initiation of mass administration of antibiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One-time mass administration only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One-time mass administration of antibiotics, plus intensive latrine construction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mass treatment with oral azithromycin to an entire community</intervention_name>
    <description>For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>F</arm_group_label>
    <arm_group_label>G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ All residents residing in the state-teams which are randomly selected for this study.

        Exclusion Criteria:

          -  Pregnant women

          -  Children under 6 months of age

          -  All those who are allergic to macrolides or azalides

          -  Refusal of village chief (for village inclusion), or refusal of parent or guardian
             (for individual inclusion)

        Individuals in these three exclusion criteria will not be given the study antibiotic
        azithromycin, but offered the current WHO-recommended alternative treatment to azithromycin
        for active trachoma, which is 1% tetracycline eye ointment, to be used twice a day,
        topically to both eyes, for six weeks. Note that the exclusion criteria refer to the
        exclusion to the treatment drug, but not to the monitoring, treatment of trachoma, and
        examinations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Lietman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Proctor Foundation, UCSF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kieran S O'Brien, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Proctor Foundation, UCSF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Emerson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carter Center, Ethiopia</name>
      <address>
        <city>Addis Ababa</city>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <reference>
    <citation>Skalet AH, Cevallos V, Ayele B, Gebre T, Zhou Z, Jorgensen JH, Zerihun M, Habte D, Assefa Y, Emerson PM, Gaynor BD, Porco TC, Lietman TM, Keenan JD. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med. 2010 Dec 14;7(12):e1000377. doi: 10.1371/journal.pmed.1000377.</citation>
    <PMID>21179434</PMID>
  </reference>
  <reference>
    <citation>Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, Hong KC, Stoller N, Ray KJ, Emerson P, Gaynor BD, Lietman TM. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA. 2009 Sep 2;302(9):962-8. doi: 10.1001/jama.2009.1266.</citation>
    <PMID>19724043</PMID>
  </reference>
  <reference>
    <citation>Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, Gaynor BD, Porco TC, Emerson PM, Lietman TM. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis. 2011 Apr 1;52(7):883-8. doi: 10.1093/cid/cir069.</citation>
    <PMID>21427395</PMID>
  </reference>
  <reference>
    <citation>Lietman TM, Gebre T, Ayele B, Ray KJ, Maher MC, See CW, Emerson PM, Porco TC; TANA Study Group. The epidemiological dynamics of infectious trachoma may facilitate elimination. Epidemics. 2011 Jun;3(2):119-24. doi: 10.1016/j.epidem.2011.03.004. Epub 2011 Apr 6.</citation>
    <PMID>21624783</PMID>
  </reference>
  <reference>
    <citation>Stoller NE, Gebre T, Ayele B, Zerihun M, Assefa Y, Habte D, Zhou Z, Porco TC, Keenan JD, House JI, Gaynor BD, Lietman TM, Emerson PM. Efficacy of latrine promotion on emergence of infection with ocular Chlamydia trachomatis after mass antibiotic treatment: a cluster-randomized trial. Int Health. 2011 Jun;3(2):75-84. doi: 10.1016/j.inhe.2011.03.004.</citation>
    <PMID>21785663</PMID>
  </reference>
  <reference>
    <citation>Keenan JD, See CW, Moncada J, Ayele B, Gebre T, Stoller NE, McCulloch CE, Porco TC, Gaynor BD, Emerson PM, Schachter J, Lietman TM. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):235-40. doi: 10.1167/iovs.11-8493.</citation>
    <PMID>22159017</PMID>
  </reference>
  <reference>
    <citation>Gebre T, Ayele B, Zerihun M, House JI, Stoller NE, Zhou Z, Ray KJ, Gaynor BD, Porco TC, Emerson PM, Lietman TM, Keenan JD. Latrine promotion for trachoma: assessment of mortality from a cluster-randomized trial in Ethiopia. Am J Trop Med Hyg. 2011 Sep;85(3):518-23. doi: 10.4269/ajtmh.2011.10-0720.</citation>
    <PMID>21896815</PMID>
  </reference>
  <results_reference>
    <citation>House JI, Ayele B, Porco TC, Zhou Z, Hong KC, Gebre T, Ray KJ, Keenan JD, Stoller NE, Whitcher JP, Gaynor BD, Emerson PM, Lietman TM. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial. Lancet. 2009 Mar 28;373(9669):1111-8. doi: 10.1016/S0140-6736(09)60323-8.</citation>
    <PMID>19329003</PMID>
  </results_reference>
  <results_reference>
    <citation>Gebre T, Ayele B, Zerihun M, Genet A, Stoller NE, Zhou Z, House JI, Yu SN, Ray KJ, Emerson PM, Keenan JD, Porco TC, Lietman TM, Gaynor BD. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. Lancet. 2012 Jan 14;379(9811):143-51. doi: 10.1016/S0140-6736(11)61515-8. Epub 2011 Dec 20.</citation>
    <PMID>22192488</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2006</study_first_submitted>
  <study_first_submitted_qc>May 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2006</study_first_posted>
  <last_update_submitted>September 5, 2015</last_update_submitted>
  <last_update_submitted_qc>September 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas M. Lietman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bacterial Infections</keyword>
  <keyword>Chlamydia Infections</keyword>
  <keyword>Eye Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlamydia Infections</mesh_term>
    <mesh_term>Trachoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

